NCT01918878View on ClinicalTrials.gov

Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration.

PHASE4UnknownINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Neovascular Age-related Macular Degeneration
Interventions
DRUG

Aflibercept (EYLEA)

INTARAVITREAL INJECTION OF AFLIBERCEPT

Trial Locations (1)

91120

Hadassah Medical Organization, Jerusalem

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Hadassah Medical Organization

OTHER

NCT01918878 - Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration. | Biotech Hunter | Biotech Hunter